The past 18 months has seen considerable advances in the use of MRI for assessment of ankylosing spondylitis, to quantify active inflammation in the spine and sacroiliac joints which may not otherwise be detectable and to therefore measure change due to therapeutic interventions.
Introduction
MRI has been increasingly used as an imaging modality in patients with ankylosing spondylitis (AS) and other spondyloarthritides due to its capacity to identify both active inflammation and chronic structural changes in the spine and sacroiliac joints. Traditionally, the structural changes of AS are assessed using conventional radiographs at those sites. According to the modified New York criteria the diagnosis/classification of AS requires radiographic changes in the sacroiliac joints of at least grade 2 unilaterally [1] . This approach does not allow a diagnosis for cases of 'early' spondyloarthritis or AS in which structural change has not yet occurred. This may, in turn, mean that a window of opportunity to treat patients before they develop irreversible bony changes may be missed. This review looks at the current role of MRI in assessing AS, and its potential in identifying early disease for early intervention.
MRI techniques
There are four MRI sequences commonly used in clinical trials in AS [2] . A T1-weighted sequence is usually used to evaluate chronic structural changes, showing normal bone marrow fat bright and giving good differentiation of anatomical structures. Acute changes consistent with inflammation can be visualized using either a T2-weighted fat suppressed fast spin echo (FSE) sequence (T2/FS), short t inversion recovery (STIR), or a T1-weighted fat suppressed FSE sequence after administration of paramagnetic contrast medium, usually gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) (T1/Gd) [3] . All three methods show acute spinal lesions bright and normal bone marrow dark. T2/FS and STIR are sensitive for detecting abnormal free water content, so that fluid collections such as bone marrow edema are seen as a hyperintense signal. T1/Gd shows inflammatory lesions bright on the basis of higher vascularity and the subsequent diffusion of contrast molecules into the interstitium [2] .
The detection of structural changes in the sacroiliac joints and, in part, the spine, remains the gold standard for the diagnosis of AS, and can be visualized using various imaging techniques including conventional radiography, computed tomography or MRI. The detection of active sacroiliitis or spondylitis in early disease stages is only possible using MRI techniques such as STIR and T1/Gd [4] . Anatomically, MRI can identify both anterior and posterior spinal changes, spondylodiscitis, discitis and arthritis and enthesitis at the smaller vertebral joints. Alongside changes in the spine and sacroiliac joints, MRI is also able to identify peripheral entheseal changes such as Achilles tendinitis and plantar fasciitis.
MRI of the sacroiliac joints
Inflammation of the sacroiliac joints is the hallmark of AS, however, it is poorly visualized on plain radiographs. Sacroiliac and spinal radiographs show late structural changes presumed to result from inflammation, including sclerosis, erosions and ankylosis, features which lag behind inflammatory changes seen on MRI [5, 6] . MRI is a sensitive technique to visualize active inflammation (Fig. 1) , and changes on T1-weighted postgadolinium sequences [7] correlate with histological evidence of inflammatory cell infiltrates. Active inflammation on MRI has been demonstrated in different anatomical regions of the sacroiliac joints in patients of both short and long disease duration [8] , confirming that AS continues to be active even in patients with marked structural damage.
A recent cross-sectional study of 18 patients with moderate to severe AS, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of greater than 4 and inflammatory back pain (IBP), looked at active sacroiliitis on MRI and its correlation with clinical markers of disease activity [9] . Abnormalities on MRI were found in 17 of the 18 patients studied. Ten had changes consistent with ongoing inflammation, including abnormal enhancement on T1-weighted sequences following gadolinium contrast and subchondral bone marrow edema. There were no significant differences between sacroiliac inflammation seen by STIR and those identified on T1-weighted sequences postcontrast, although the authors felt the changes were more marked on postcontrast films. MRI changes were graded as 1 (mild), 2 (moderate) or 3 (severe). Findings on MRI were analyzed for correlation to clinical markers of disease activity, including BASDAI, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Functional Index (BASFI), back pain scores, disease duration and radiograph changes assessed by the Bath Ankylosing Spondylitis Radiology Index (BASRI). Only CRP was shown to be related to disease activity on MRI, with mean CRP in patients without abnormal enhancement or subchondral bone marrow edema on MRI being 0.55, compared with 6.4 in those showing MRI changes of active inflammation (P ¼ 0.04). Although CRP (and ESR) are considered to be of limited value in assessing inflammation in AS, with up to 40% of patients never recording elevated acute phase reactants, CRP and MRI are, nevertheless, the main basis for providing objective evidence for inflammation in patients with ankylosing spondylitis. The numbers in the study, however, are small and statistical power is limited. The study confirms that radiographs are insensitive for identifying active inflammation in AS, and this has important implications for early diagnosis and intervention.
Several scoring systems have been developed to quantify MRI changes of the sacroiliac joints in AS, the earliest in 1996 [10] . Most recently, the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index for assessment of sacroiliac joint inflammation in AS has been reported [11] . Similarly to earlier scoring systems, each sacroiliac joint is divided into four quadrants (upper iliac, lower iliac, upper sacral and lower sacral). In the SPARCC system, the presence of an increased signal on STIR in each quadrant is scored dichotomously, as 0 for a normal signal or 1 for an increased signal. The maximum score for an abnormal signal in the two sacroiliac joints of one coronal slice is therefore 8. Joints that include a lesion exhibiting an intense signal are each given an additional score of 1 per slice that demonstrates this feature. Similarly, each joint that includes a lesion demonstrating continuous increased signal of depth 1 cm from the articular surface is also given an additional score of 1. This brings the maximal score for a single coronal slice to 12. Six consecutive coronal slices are scored, giving a final score between 0 and 72.
The Assessments in Ankylosing Spondylitis (ASAS) international working group, in collaboration with Outcome Measures in Rheumatology (OMERACT) have published a comprehensive study on the measurement properties of the different available scoring methods [12] . The authors conclude that intrareader reliability was good for all methods of measuring acute sacroiliac inflammation (Aarhus, MISS, Leeds, SPARCC and two Berlin systems)
Ankylosing spondylitis Zochling et al. 347 T1/Gd sequence shows marked osteitis and anterior capsulitis of the paraarticular bone marrow of the left sacroiliac joint (SIJ) (arrows). There are only few erosions and mild sclerosis. There are also discrete inflammatory changes on the right SIJ and the L5/S1 intervertebral disk (arrowheads). [13] . Overall there was no evidence to rank the different scoring systems, and further research into scoring of the sacroiliac joints in AS was recommended.
MRI of the spine
Active inflammation of spinal structures, including the intervertebral disc, the vertebra, enthesis of interspinal ligaments, costovertebral joints and zygapophyseal joints have all been identified by MRI, however, until now histopathological correlation of these findings has been lacking. Appel and colleagues [14 ] have now examined the relationship between abnormal fluid signal on MRI, read as acute inflammation, and the histological presence of bone marrow edema and inflammatory cell aggregates in the zygapophyseal joints. Specimens from eight AS patients and 10 controls without rheumatic disorders were examined. All AS specimens showed varying amounts of interstitial bone marrow edema, whereas none was seen in control samples. MRI identified zygapophyseal bone marrow oedema in three of the eight AS patients, interestingly those with the highest proportion of histological edema (30-60% of the total bone marrow area studied). An increased signal was also seen at other spinal sites. On the basis of this study, it can be concluded that MRI does identify histopathological inflammation at this site, however, it may not be sensitive enough to detect low levels of inflammation. Inflammatory cell infiltrates did not correlate well with either bone marrow edema on histology or on MRI, further evidence that some patients with active disease remain difficult to identify in the clinical setting despite newer imaging techniques.
Using MRI, active inflammatory changes can be identified at all levels of the spine. A systematic survey of spinal MRIs in 38 patients with AS (mean age 40.9 years, 63% male, 92% HLA-B27 positive) [15] recently described the distribution of inflammatory lesions throughout the spine, revealing that inflammation appears more commonly in the lower part of the thoracic spine than the cervical or lumbar regions, independent of the MRI sequence used. Twenty-eight (74%) of patients studied had definite inflammatory changes at the thoracic spine. Another group has shown the costovertebral joints also show a high frequency of inflammatory change on MRI [16, 17] . Assuming inflammatory lesions in the spine may progress to structural damage, the preference for thoracic spinal structures is particularly important when assessing plain radiographs which poorly visualize the thoracic spine, and suggests that current radiograph scoring systems which omit the thoracic spine may well underestimate the burden of disease in any one individual. Indeed, examination of the same cohort for chronic spinal changes on MRI confirmed that structural change is more common at the thoracic spine, seen in 21 (58%) of the patients studied [18] . In the same study, chronic changes were seen in similar vertebral levels to acute inflammatory changes in the same patients.
Both STIR and T1/Gd sequences are sensitive for measuring spinal inflammation. Comparatively, T1/Gd has the disadvantage of requiring contrast and is therefore more invasive, time consuming and costly, whereas STIR gives a lower signal-to-noise ratio and thus may be less sensitive in visualizing acute inflammatory lesions. Formal comparison of the two methods has recently been reported by Hermann and colleagues [2] . A random sample of 48 patients was taken from 279 AS patients enrolled in a randomized placebo-controlled trial of infliximab in active AS [19] . STIR and T1/ Gd sequences were performed at baseline and at 6 months, and scored by two readers for acute changes using the AS spinal MRI activity (ASspiMRI-a) score and for quality of the image using a five-point Likert scale, with 1 representing very poor image quality -not able to be read, and 5 indicating excellent image quality. Despite consistent small systematic differences between the two readers' scores, both STIR and T1/Gd were found to be valid and reliable, and image quality was not significantly different between methods. As seen in earlier studies [20, 21] T1-Gd was marginally more sensitive for acute inflammatory lesions than STIR. This did not represent an important difference in the setting of a clinical trial.
Scoring systems have been developed for reporting both acute and chronic spinal MRI changes in AS. The ASspiMRI-a [21] quantifies bone marrow edema (score 1-3) and erosions (4-6) for each of 23 vertebral units from C2 to S1, taken from the mid point of one vertebral body to the mid point of the vertebral body below and thus including one entire intervertebral disc, giving an activity score for each vertebral unit between 0 and 6 and a possible total score of 138. The scoring system is reliable and sensitive to change over 3-6 months, and has been used in most clinical trials published so far [22 ,23-25] . The Berlin method is an adaptation of the ASspiMRI-a, with similar scoring omitting the erosions, giving a potential maximum score of 69. The most recent method to be described is the SPARCC MRI index for assessment of spinal inflammation in AS [26] . Also based on the vertebral unit, each vertebral unit is read in quadrants and scored as 0 (normal) or 1 (abnormal) for each of three sagittal slices. Similar to the SPARCC scoring system for sacroiliitis, one additional score is possible for each quadrant when a lesion with intense signal or depth of at least 1 cm is present, giving a possible maximum score of 18 per vertebral unit. In contrast to the ASspiMRI-a, only the six most apparent lesions on STIR are scored using this system, limiting the possible total score to 108. The SPARCC system is reliable with intraobserver ICCs of between 0.85 and 0.98, and the method was also shown to be responsive to 24 weeks of anti-tumour necrosis factor (TNF) treatment.
Akin to the ASspiMRI-a, the ASspiMRI-c scores vertebral units for structural changes seen in established ankylosing spondylitis. Erosions, sclerosis, squaring, syndesmophytes, bridging and fusion are scored semiquantitatively from 0 which indicates normal to 6 which represents complete fusion, again giving a possible total score of 138. This is the only validated scoring system in use for chronic spinal changes. One possible advantage of the ASspiMRI-c is that the thoracic spine may be more reliably scored than by radiography.
Role of MRI in diagnosis of ankylosing spondylitis
The detection and localization of inflammation in the sacroiliac joints and the spine is obviously relevant for the early diagnosis of spondyloarthritis including AS, as these changes are identifiable earlier than with conventional radiographs. The possibility of a patient with IBP having axial spondyloarthritis or early AS rises by a factor of 10 when typical MRI changes are present [27, 28] . The precise role of MRI in daily practice, however, is not well defined because more simple clinical parameters such as IBP and HLA B27 have a relatively high sensitivity and the performance of MRI in HLA B27-negative patients with chronic back pain not fulfilling the criteria for IBP but possible spondyloarthritis has not been well studied. Recently, Heuft-Dorenbosch and colleagues [29 ] reviewed the performance of different classification criteria sets for spondyloarthritis, including the Berlin diagnostic algorithm, in a cohort of 68 patients with a minimum of 2 years' duration of IBP. The Berlin criteria, unlike the European Spondyloarthropathy Study Group (ESSG), Amor and modified New York criteria, include MRI alongside HLA-B27 and clinical parameters to estimate the likelihood of a patient having a diagnosis of axial spondyloarthritis. It was shown that the ESSG criteria are the most sensitive to diagnose spondyloarthritis, with 57 patients fulfilling the ESSG criteria, and the modified New York criteria the most specific (14 patients). Inclusion of MRI data did not add a great deal to the clinical diagnosis. The explanation for this, however, may be that IBP, which is an essential part of the ESSG criteria, was the main inclusion criterium. When the same data set was analysed to study the usefulness of MRI in cases of clinically likely AS with normal radiographs [30] , the results showed that radiographs are useful in about 20% of patients with IBP of less than 2 years' duration, while MRI was helpful in more than 30%. Nevertheless, the advantage of including MRI in routine clinical practice for the purposes of making the diagnosis of spondyloarthritis needs to be carefully discussed. Given the high prevalence of back pain in the population, the main question is whether general practitioners should order an MRI or whether they should transfer patients with IBP and patients with chronic back pain who are HLA B27 positive to the rheumatologist [31] . In conclusion, it seems clear that MRI of the sacroiliac joints is helpful in a clinical situation when objective evidence of sacroiliitis is needed. Its use will rather increase the specificity than the sensitivity of diagnosing spondyloarthritis early since the majority of patients are likely to have IBP, although the recently proposed criteria have not yet been evaluated in patients with early spondyloarthritis. MRI, nevertheless, provides a rather good overview of the anatomy and pathology of the sacroiliac joint and the spine and it has the unique ability to visualize both active and chronic changes at a time. On that basis, MRI has a clear role in the early diagnosis of spondyloarthritides, while its predictive value for a development to ankylosing spondylitis needs more study. Finally, besides its diagnostic value, MRI is the only imaging technique to show ongoing inflammation. This may well have therapeutic implications.
Typical entheseal changes associated with spondyloarthritis can occur at peripheral joints [32] , axial joints like the hip and shoulder, and at multiple spinal sites. The typical lesion is bone marrow edema which occurs more often in spondyloarthritis than in rheumatoid arthritis [31] . MRI is a good method for visualizing active enthesitic changes as it captures both soft-tissue changes and intraosseous abnormalities, but ultrasound also has a good capacity in experienced hands in this regard. The wide range of potential entheseal sites affected in spondyloarthritis has recently been reviewed in depth, outlining the typical site-specific changes seen on MRI [33 ]. Recent technical developments enable whole-body MRI imaging within about 60 min, and thus depicting the majority of entheses involved in spondyloarthritis [34] . This technique may play a role in the future when multifocal enthesitis is suspected and needs objective proof. Scintigraphy may also be useful in clinical situations when several different enthesitic sites are searched for, but requires exposure of ionizing radiation to the patient. Visualization of enthesitis may well have a place in specific patient situations requiring an objective diagnosis of enthesitis when other methods are equivocal or impractical.
Role of MRI in measuring treatment response in clinical trials
Due to a combination of its sensitivity in detecting acute inflammatory change, the existence of valid and reproducible MRI scoring systems and the absence of other reliable objective measures of disease activity in AS, MRI has been increasingly used as a surrogate endpoint in clinical trials of anti-TNF agents.
The most recent results from ongoing studies of infliximab and etanercept in ankylosing spondylitis show that active spinal inflammation as seen on MRI responds rapidly to treatment with anti-TNF agents and remains suppressed with long-term therapy (Fig. 2 ). Braun and colleagues [22 ] report on MRI findings from the Ankylosing Spondylitis Study for the Evaluation of Recombinant infliximab Therapy (ASSERT) trial, to date the largest randomized controlled trial of anti-TNF therapy (infliximab) in AS. One hundred and ninety-four patients were randomized to receive infliximab at 5 mg/kg at weeks 0, 2, 6 and then 6-weekly for 24 weeks, and 72 received placebo. All had MRI using T1-weighted pre-and postgadolinium and STIR sequences at baseline and at 24 weeks. At baseline, 80% of all participants had at least one active spinal inflammatory lesion on MRI, as would be expected in a cohort of patients who required a BASDAI of at least 4 for entry into the trial. At 24 weeks the infliximab group showed a mean improvement in ASspiMRI-a score of 5.02 compared with a deterioration of 0.60 in the placebo group, P < 0.001. On an individual level, most patients showed near-complete resolution of spinal inflammation with infliximab therapy, irrespective of the baseline activity. Open label extension studies of infliximab therapy confirm that the suppression of spinal inflammation on MRI persists out to 2 years [23, 35] . In both trials, low-grade MRI changes of inflammation were still detectable at the end of the study.
Similar findings have been seen in smaller etanercept trials. Spinal inflammation seen on both STIR and T1weighted Gd-DTPA sequences showed regression with etanercept as early as 6 weeks compared with placebo in 18 AS patients [24] , with an overall reduction in active spinal lesions at 24 weeks of 69%. Inflammation at the sacroiliac joints did not show such a dramatic improvement, with changes not reaching statistical significance. Baraliakos and colleagues [25] showed similar spinal changes at 24 weeks in 40 patients treated with etanercept. Lesions were reduced by an average of 54% in the treatment group compared with a worsening of 13% in the placebo arm of the trial (P < 0.001). This corresponded to a mean ASspiMRI-a score change from 1.33 to 0.61 per vertebral unit in the etanercept group, and 0.94 per vertebral unit at baseline in the placebo group increasing to 1.06 per vertebral unit at 12 weeks. No structural deterioration was seen in the treatment arm. Again, treatment did not result in complete resolution of active inflammatory changes on MRI at 12 weeks, and when 26 of these patients were reexamined after 2 years of open-label etanercept therapy all but one patient still had at least one inflammatory lesion on MRI [35] . Adalimumab therapy shows a similar magnitude of MRI regression after 52 weeks [36] .
The presence of residual low-grade inflammatory lesions at the spine after therapy with anti-TNF agents raises some concerns. The clinical significance of this level of MRI change is not clear, but it may be that ongoing disease activity has some implications for disease progression and ongoing structural damage despite the apparent treatment response. So far there has been no convincing evidence that biologic therapy has a structure-modifying effect in AS, despite studies now reaching out to 5 years of treatment.
Conclusions
MRI has become a standard tool for measuring outcome in clinical trials in AS, and its ability to identify both active inflammatory changes at the spine and sacroiliac joints and more chronic structural abnormalities makes it an ideal imaging technique to assess both the acute symptoms of disease and the longer-term consequences in a clinical trial setting. Its role in daily practice, in the diagnosis of AS and assessment of treatment response is not yet clear. MRI cannot be recommended as a first line investigation in the patient with AS, but may add important information in difficult cases.
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